Delivery Order SPE2DE22D0008-SPE2D626F7121
- Not listed
- The Defense Logistics Agency's Medical Supply Chain division awarded a $12,080 delivery order to Alba Bioscience, Inc. for ALBACLONE Anti-E monoclonal antibodies under a firm fixed price contract. The award, issued on October 30, 2025, with an ultimate completion date of November 4, 2025, represents a competitive procurement with no set-aside designation. Alba Bioscience, a Chicago-based subsidiary of Quotient Biodiagnostics, Inc., specializes in providing in vitro diagnostic products and...
- Alba Bioscience, Inc. was awarded a delivery order valued at $1,123.00 by the Medical Supply Chain division of the Defense Department on July 29, 2025, with an ultimate completion date of August 1, 2025. The contract, identified as 4568920078, covers the supply of ALBACLONE Anti-A antibodies, specialized reagents used in blood banking and immunohematology testing. This non-set-aside award was issued under a firm fixed-price arrangement, with performance to be completed in Chicago, Illinois. Alba...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $1,115.79 to Alba Bioscience, Inc. for the ALBACYTE Antibody ID Panel (16-Cell) on October 30, 2025, with an ultimate completion date of January 7, 2026. The contract is a firm fixed-price delivery order with no set-aside designation, reflecting Alba Bioscience's competitive standing as a specialized supplier of immunohematology reagents and blood banking diagnostic materials. Alba Bioscience, a...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded Alba Bioscience, Inc. a $9,500 delivery order on October 30, 2025, for an ALBACYTE Antibody ID Panel (10-Cell) with a completion date of January 7, 2026. This firm fixed-price delivery order represents a competitive procurement without set-aside designation, leveraging Alba Bioscience's specialized capabilities in immunohematology reagents and blood banking diagnostics. Alba Bioscience, a Chicago-based subsidiary of...
- Alba Bioscience, Inc., a Chicago-based supplier of in vitro diagnostics and blood bank reagents, was awarded a delivery order for ALBACYTE Antibody ID Panel (10-Cell) on June 2, 2025, with a ceiling value of $12,895. The contract is a firm fixed price delivery order with an ultimate completion date of August 6, 2025, and was issued without a set-aside designation, indicating competitive procurement. The award was funded by the Defense Logistics Agency's Medical Supply Chain division,...
- Alba Bioscience, Inc. was awarded a delivery order contract by the Defense Logistics Agency's Medical Supply Chain division on August 14, 2025, for the supply of ALBACLONE Anti-D Blend, a specialized blood bank reagent used in immunohematology testing. This firm fixed-price contract carries a ceiling value of $1,464.00 with an ultimate completion date of August 19, 2025. The contract was awarded on a non-competitive basis with no set-aside designation, reflecting Alba Bioscience's established...
- The U.S. Defense Logistics Agency, operating under the Medical Supply Chain division, awarded a delivery order contract to Alba Bioscience, Inc. for ALBACLONE anti-FYB antibody screening products. The contract, valued at $12,875 with a firm fixed price structure, was executed on September 4, 2025, with an ultimate completion date of September 9, 2025. This non-set-aside award represents a continuation of Alba Bioscience's established role as a critical supplier of specialized in vitro diagnostic...
- Alba Bioscience, Inc. received a $2,030 firm fixed-price delivery order from the Department of Defense's Medical Supply Chain on June 5, 2025, for the ALBACYTE Antibody ID Panel (16-Cell). The contract, which carries an ultimate completion date of August 11, 2025, was awarded without a set-aside designation, reflecting Alba Bioscience's competitive standing as a supplier of specialized in vitro diagnostic products. Performance will take place in Chicago, Illinois, where the vendor maintains...
- The Defense Logistics Agency, operating under the Defense or Civilian designation, awarded a delivery order contract (4568409675) to Alba Bioscience, Inc. on June 2, 2025, for the supply of ALBACLONE Anti-K antibodies. The contract represents a firm fixed price delivery order with a ceiling value of $15,944.00 and an ultimate completion date of June 5, 2025. The award was made on a non-set-aside basis, reflecting Alba Bioscience's competitive standing as an established supplier of specialized...
- This is a firm fixed-price delivery order contract awarded by the Medical Supply Chain division of the U.S. Department of Defense (Defense) to Alba Bioscience, Inc., a for-profit organization specializing in in vitro diagnostics and blood bank reagents. The $1,239.00 contract is for the supply of ALBACYTE antibody screening (2-cell) products, with a period of performance through August 11, 2025. Alba Bioscience, Inc. holds multiple significant federal contract Indefinite Delivery Vehicles...
- SPE2DE22D0008Indefinite Delivery Contract
- SPE2DE22D0008-SPE2D626F7121Delivery Order
Alba Bioscience, Inc., a Chicago-based diagnostic supplier specializing in immunohematology reagents and blood banking materials, was awarded a $4,740 delivery order by the Defense Logistics Agency's Medical Supply Chain division on October 30, 2025, for ALBACLONE Anti-B monoclonal antibodies. The contract, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by November 4, 2025, and will be performed in Chicago, Illinois. This delivery order represents a continuation of Alba Bioscience's established role as a critical supplier of blood banking diagnostic products to federal healthcare systems, leveraging the company's specialized capabilities in providing in vitro diagnostics essential for transfusion services and antibody screening operations. Alba Bioscience maintains two significant Blanket Purchase Agreements with the Department of Veterans Affairs under GSA Schedule 65-VII that serve as indefinite delivery vehicles for procuring blood banking supplies across multiple VA medical facilities nationwide. The first BPA, valued at $199,671.75 and extending through May 31, 2030, was awarded to Veterans Integrated Service Network 15, while the second, valued at $218,840.70 and extending through September 30, 2026, supports Veterans Integrated Service Network 10. These vehicles enable VA facilities to efficiently order critical products from Alba Bioscience's comprehensive portfolio, which includes monoclonal antibodies, antibody identification and screening panels, quality control kits, and specialized cell reagents, demonstrating sustained demand across the integrated VA healthcare system for the company's specialized diagnostic offerings.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 10/30/25 |